Life Sciences

One of the more exciting areas of growth within our Life Sciences Division over the year has been the establishment of services designed to support the development of gene therapy. Gene therapy is designed to introduce genetic material into cells to compensate for abnormal genes or to make a beneficial protein. A gene that is

At Pace Analytical we understand the importance of keeping up with changes in the marketplace. On March 1, 2019, a revision of USP <467>, Residual Solvents, will become effective. This revision clarifies verification and validation requirements for use of the monograph for Class 1, 2, and 3 residual solvent determination in compendial and non-compendial materials.

February 14, 2019 – Andrew Wheeler, the acting administrator of the Environmental Protection Agency (EPA), announced a set of comprehensive actions to address the presence of Per- and Polyfluoroalkyl Substances (PFAS) in the environment. The actions will provide a framework for the future monitoring, detection, and clean-up of PFAS and leverage multiple programs and disciplines.

In conjunction with BIO International 2018, Pace Analytical Life Sciences is celebrating its first full year in Boston! Last year, Pace Analytical announced the acquisition of Wolfe Laboratories, Inc., a leading translational contract drug development company in the Boston area. The combined capabilities of the two organizations now offer the life science industry a one-stop-shop

Pace Analytical Life Sciences (PLS) has recently made significant investments to upgrade our capabilities and capacity for Total Organic Carbon (TOC) USP/EP testing. We have upgraded and standardized our equipment: we have purchased three new instruments and placed one within each of our FDA-registered, GMP-compliant testing laboratories: Oakdale, Minnesota Somerset, New Jersey San German, Puerto